Back to top
more

Glaukos (GKOS)

(Delayed Data from NYSE)

$130.98 USD

130.98
397,877

+4.18 (3.30%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $130.94 -0.04 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (61 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Cynosure (CYNO) to be Acquired by Hologic in $1.65B Deal

Cynosure, Inc. (CYNO), announced that it has entered into a definitive merger agreement with Hologic, Inc. (HOLX).

    Express Scripts (ESRX) Earnings Top, Revenues Lag in Q4

    Express Scripts Holding Company (ESRX) posted fourth-quarter 2016 adjusted earnings per share of $1.88, beating the Zacks Consensus Estimate by a penny

      Genomic Health (GHDX) Earnings Surpass Estimates in Q4

      Genomic Health, Inc. (GHDX) reported fourth-quarter 2016 earnings per share of 4 cents, reflecting an improvement from the year-ago quarter's loss figure of 8 cents.

        Becton, Dickinson Launches BD Resolve Early Access Program

        Leading global medical technology company, Becton, Dickinson and Company (BDX), popularly known as BD, recently announced an early access program for the BD Resolve Single-Cell Gene Expression platform.

          Medtronic (MDT) Adds New Tools, Expands Coronary Suite

          Medtronic plc (MDT) recently added DxTerity Diagnostic Angiography Catheter line and several transradial-specific products to its market-leading coronary portfolio.

            Bruker (BRKR) Beats on Q4 Earnings, Issues 2017 Guidance

            Bruker Corporation (BRKR) reported fourth quarter 2016 adjusted EPS of 46 cents, up 21.1% year over year and also surpassed the Zacks Consensus Estimate of 37 cents.

              Omnicell Partners with DCH Health for Sterile Compounding

              Omnicell, Inc. (OMCL) recently formed an alliance with West Alabama's community-based health service provider, DCH Health System on sterile compounding operations.

                Varian (VAR) Wins Competitive Bid for Six Shanghai Hospitals

                Varian Medical Systems, Inc. (VAR) recently announced that it has won a competitive bid in Shanghai.

                  STERIS (STE) Cuts 2017 View: Will it See Gloomy Days Ahead?

                  On Feb 09, we issued an updated research report on Ohio-based STERIS plc (STE).

                    Mead Johnson-Reckitt Benckiser Mega Deal: A Strategic Fit?

                    Pediatric nutrition manufacturer Mead Johnson Nutrition Company (MJN) recently announced an agreement to be acquired by British consumer-products maker, Reckitt Benckiser Group plc.

                      Cerner (CERN) Q4 Earnings Meet, Revenues Miss Estimates

                      Cerner Corp(CERN) reported adjusted fourth-quarter 2016 earnings of 57 cents per share, in line with the Zacks Consensus Estimate.

                        NuVasive (NUVA) Beats Q4 Earnings, Revenues; Guides 2017

                        NuVasive, Inc. (NUVA) reported fourth-quarter 2016 adjusted earnings per share (EPS) of 53 cents, reflecting a 51.4% surge from the year-ago quarter.

                          Will Glaukos (GKOS) Continue to Surge Higher?

                          As of late, it has definitely been a great time to be an investor in Glaukos Corp (GKOS).

                            Myriad Genetics (MYGN): Q2 Impressive, 2017 View a Drag

                            On Feb 8, we issued an updated research report on Salt Lake City, UT-based molecular diagnostic company Myriad Genetics Inc. (MYGN).

                              Zimmer Biomet (ZBH) Launches Subchondroplasty Procedure

                              Zimmer Biomet Holdings, Inc. (ZBH), a leading player in the musculoskeletal healthcare space, recently announced the global launch of its Subchondroplasty (SCP) Procedure.

                                CVS Health (CVS) Beats on Q4 Earnings, Retains '17 View

                                CVS Health Corporation (CVS) reported fourth-quarter 2016 adjusted earnings per share (EPS) of $1.71, up 11.8% year over year.

                                  Quest Diagnostics Partners with Veracyte for Cancer Testing

                                  Quest Diagnostics Incorporated (DGX) has recently entered into an agreement with genomic diagnostics company Veracyte, Inc. (VCYT), for the extended access of Afirma Gene Expression Classifier (GEC).

                                    Myriad Genetics (MYGN) Beats on Q2 Earnings, Narrows View

                                    Myriad Genetics Inc. (MYGN) reported adjusted earnings per share (EPS) of 26 cents in the second quarter of fiscal 2017, down 42.2% year over year.

                                      Steris (STE) Q3 Dismal: Earnings Miss Estimates, View Cut

                                      Steris Plc (STE) reported third-quarter fiscal 2017 adjusted earnings per share (EPS) of 98 cents, in line with the year-ago quarter.

                                        Haemonetics (HAE) Beats Q3 Earnings & Revenue Estimates

                                        Haemonetics Corporation (HAE) reported adjusted earnings per share (EPS) of 43 cents in the third quarter of fiscal 2017, beating the Zacks Consensus Estimate by 7.5%.

                                          Cardinal Health (CAH) Q2 Earnings Beat Estimates, Rise Y/Y

                                          Cardinal Health Inc. (CAH) reported second-quarter fiscal 2017 adjusted earnings of $1.34 per share, which beat the Zacks Consensus Estimate of $1.24 and increased 3% on a year-over-year basis.

                                            Luminex (LMNX) Posts Loss in Q4, Revenues Miss Estimates

                                            Luminex Corporation (LMNX) reported loss of 8 cents per share in the fourth quarter of 2016, comparing unfavorably with the Zacks Consensus Estimate of adjusted earnings of 4 cents per share.

                                              Phirbo Animal (PAHC) Tops Q2 Earnings, Reaffirms FY17 View

                                              Phibro Animal Health Corporation (PAHC) reported adjusted earnings per share (EPS) of 39 cents in the second quarter of fiscal 2017.

                                                SurModics (SRDX) Beats Earnings & Revenue Estimates in Q1

                                                Surmodics, Inc. (SRDX) reported earnings of 19 cents per share in the first-quarter of fiscal 2017 surpassing the Zacks Consensus Estimate of 9 cents.

                                                  Pacific Biosciences (PACB) Q4 Loss Narrower than Estimated

                                                  Pacific Biosciences of California Inc. (PACB), a pioneer in the field of single molecule long resequencing, reported loss of 21 cents per share in the fourth quarter of 2016, 2 cents narrower than the Zacks Consensus Estimate.